Treatment of pain using placental stem cells

• US 9,040,035 B2
• Filed: 05/31/2012
• Issued: 05/26/2015
• Est. Priority Date: 06/01/2011
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Herzberg, Uri, Gurney, Jodi P.
• Primary Examiner(s): Long, Scott
• Application Number:
  US13/485,161
• Publication Number:
  US 20120328583A1
• Time in Patent Office: 1,090 Days
• US Class Current: 424/93.21
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources

Abstract

Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).

Claims

1. A method of treating neuropathic pain in an individual, comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein (i) said placental stem cells express one or more genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs), wherein said one or more genes are ELOVL2, ST3GAL6, ST6GALNAC5, and/or SLC12A8, (ii) the therapeutically effective amount is an amount sufficient to cause a detectable improvement in said neuropathic pain, and (iii) said neuropathic pain is caused by a drug, wherein said drug is or comprises a platinum-containing anticancer drug or paclitaxel.

2. The method of claim 1, wherein said method additionally comprises determining one or more first levels of pain in said individual prior to administration of said placental stem cells, and determining one or more second levels of pain in said individual after administration of said placental stem cells, wherein said therapeutically effective amount of placental stem cells reduces said one or more second levels of said pain as compared to said one or more first level of pain.

3. The method of claim 2, wherein said one or more first levels of pain and said one or more second levels of pain are determined by a pain assessment scale.

4. The method of claim 3, wherein said pain assessment scale is the Numeric Pain Intensity Scale;

the Pain Quality Assessment Scale;

the Simple Descriptive Pain Intensity Scale;

the Visual Analog Scale;

the Wong-Baker FACES Pain Rating Scale;

the FLACC scale;

the CRIES scale;

the COMFORT scale;

or evoked pain measure induced by subjecting the patient to cold, heat or mechanical stimuli.

5. The method of claim 1, wherein said method additionally comprises determining a first level of one or more physiological indicia of pain in said individual prior to administration of said placental stem cells, and determining a second level of one or more physiological indicia of pain in said individual after administration of said placental stem cells, wherein said therapeutically effective amount of placental stem cells reduces said second level as compared to said first level.

6. The method of claim 5, wherein said physiological indicium of pain is heart rate in the individual.

7. The method of claim 6, wherein said heart rate in said individual is lower after said administration compared to said heart rate in said individual before said administration.

8. The method of claim 5, wherein said physiological indicium of pain is the systolic of said individual.

9. The method of claim 8, wherein said systolic of said individual is lower after said administration compared to said systolic in said individual before said administration.

10. The method of claim 5, wherein said physiological indicium of pain is the diastolic of said individual.

11. The method of claim 10, wherein said diastolic of said individual is lower after said administration compared to said diastolic in said individual before said administration.

12. The method of claim 1, wherein said one or more genes additionally comprise one or more of ARTS-1, IER3, IL6, KRT18, LRAP, MEST, NFE2L3, or TGFB2.

13. The method of claim 1, wherein said platinum-containing anticancer drug is or comprises oxaliplatin, carboplatin or cisplatin.

14. The method of claim 1, wherein said placental stem cells are administered locally.

15. The method of claim 1, wherein said placental stem cells are administered systemically.

16. The method of claim 1, wherein said placental stem cells are administered intravenously.

17. The method of claim 1, wherein said placental stem cells are administered intraarterially.

18. The method of claim 1, wherein said placental stem cells are administered intramuscularly.